Debra Lukenbill, NP
Family · Williston, NDNPI 1265456370
Payments from drug & device makers
Across 36 payments — averaging $17.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$175
- Takeda Pharmaceuticals U.S.A., Inc.$106
- Alkermes, Inc.$102
- Sunovion Pharmaceuticals Inc.$93
- Lundbeck LLC$34
- E.r. Squibb & Sons, L.L.C.$31
- plus $78 from 4 others
What the payments were for
- Food & beverage$53987%
- Education$7913%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $175 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $106 |
| Alkermes, Inc. | 6 | $102 |
| Sunovion Pharmaceuticals Inc. | 9 | $93 |
| Lundbeck LLC | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 1 | $31 |
| Orexo US, Inc. | 1 | $25 |
| AstraZeneca | 1 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
| AbbVie | 1 | $14 |
How this compares
$619 in reported general payments places this provider in the 75th percentile of 496 family providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 133 | $4,742 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 128 | $1,897 |
| Vilazodone Hcl | 21 | $1,289 |
| Bupropion XlBupropion Hcl | 61 | $1,093 |
| Quetiapine Fumarate | 69 | $855 |
| Aripiprazole | 76 | $846 |
| Duloxetine Hcl | 46 | $747 |
| Buspirone Hcl | 38 | $717 |
| Lurasidone Hcl | 26 | $664 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 19 | $545 |
| Trazodone Hcl | 71 | $438 |
| Olanzapine | 44 | $419 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 11 | $416 |
| Ziprasidone Hcl | 11 | $370 |
| Lorazepam | 97 | $307 |
Paid to pharmacies, not to this prescriber.
Other family in Williston
- Christina DahlJamestown$26K
- Coralyn Jensen KurtzGrand Forks$12K
- Paula RickeGrand Forks$9K
- Courtney WoodburyBismarck$8K
- Monica GoetzBismarck$8K
- Danielle EidenschinkFargo$6K
- Chantel HillestadMinot$6K
- Elizabeth ScheurerBismarck$6K
- Kayla HolzerBismarck$5K
- Amanda AllmarasBismarck$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.